Mcp

Metoclopramide, the active ingredient in Mcp, is a dopamine antagonist (antiemetic) presented as an oral tablet for oral use. It is used to treat nausea, vomiting, gastroparesis, gastro‑oesophageal reflux disease and to prevent chemotherapy‑induced nausea in adults. GNH USA supplies Mcp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide acts on the dopaminergic pathways that trigger nausea and impair gastric motility.

- Nausea and vomiting: reduces the frequency and severity of acute and delayed episodes. - Gastroparesis: enhances gastric emptying and improves related symptoms. - Gastro‑oesophageal reflux disease (GERD): increases lower esophageal sphincter tone to reduce reflux. - Chemotherapy‑induced nausea: prevents emesis associated with cytotoxic treatment.

Metoclopramide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness - Fatigue - Restlessness or akathisia - Diarrhea - Dry mouth - Headache

Serious or Rare Side Effects: - Extrapyramidal symptoms (e.g., dystonia, parkinsonism) - Tardive dyskinesia with long‑term use - Neuroleptic malignant syndrome - Severe allergic reactions (anaphylaxis, skin rash) - Depression or suicidal thoughts - Cardiac arrhythmias

Before prescribing Metoclopramide, clinicians should consider several safety measures. - Assess renal function: dose adjustment may be needed in impairment. - Monitor for extrapyramidal symptoms: observe patients for movement disorders. - Avoid in patients with known hypersensitivity: discontinue if reaction occurs. - Use caution in the elderly: increased susceptibility to CNS effects. - Do not combine with other dopamine antagonists: risk of additive adverse effects. - Store at room temperature: keep in the original pack, protect from moisture.

Metoclopramide can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): may increase extrapyramidal risk. - Monoamine oxidase inhibitors (MAOIs): can potentiate central nervous system effects. - CNS depressants (e.g., benzodiazepines): may enhance sedation.

Moderate Interactions (Monitor Closely): - Opioids: may augment gastrointestinal side effects. - Selective serotonin reuptake inhibitors (SSRIs): potential for serotonin syndrome. - Antihistamines: may increase drowsiness.